CGN Nuclear Technology Development Co Ltd (CGNNT, 000881.SZ), a subsidiary of China General Nuclear Power Corporation (CGN), and Shanghai Research Institute of Chemical Industry (SRICI) reached a strategic cooperation agreement on promoting the application of China's nuclear technology during a promotion event, which was held in Beijing on June 21.
Feng Yi, vice-president of CGNNT, and Li Liangjun, president of SRICI, signed the agreement on behalf of the two sides.
The two parties, citing the market demand for nuclear technology, will carry out technical research and industrial cooperation in the fields of national key strategic emerging industries including stable isotope separation, labeling compound product preparation, isotope detection reagents, isotope materials, and modified polymer materials.
According to the announcement, they will build a joint research institute, train nuclear technology professionals, and promote research and development of new technologies and applications in China's nuclear technology by giving full play to their respective advantages.
C13 isotope is a good tracer with advanced technology and good economic returns. At present, only the United States, Japan, and Russia have this kind of production technology. China depends on imports.
Before signing the agreement, the two sides jointly undertook a nuclear energy development project for the State Administration of Science, Technology, and Industry for National Defense, which was called "key technology development of C13 isotope production and industrialization". They also started the construction of the demonstration production line for the first domestic low temperature rectification production of C13 isotope.
Upon completion, it is expected to fill key technology gaps for domestic C13 isotope production and break the international market monopoly, which will help promote related industries.
C13 isotope can be used in many fields such as traditional agriculture, organic synthesis, nutrition research, ecological environment management, life sciences, nuclear power, and medicine.
It also displays huge potential for developing new drugs, food safety testing, clinical diagnosis, precision manufacturing, breeding, security monitoring, and other emerging high-tech fields.
Industry experts predict that the potential demand for C13-breath test scale-application will be 200 million person-time. Its domestic market will reach 12 billion yuan ($1.75 billion) by 2030 and its application in other fields will also reach billions of dollars.